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Reduced brain UCP2 expression mediated by
microRNA-503 contributes to increased stroke
susceptibility in the high-salt fed stroke-prone
spontaneously hypertensive rat
Speranza Rubattu*,1,2, Rosita Stanzione2, Franca Bianchi2, Maria Cotugno2, Maurizio Forte2, Floriana Della Ragione2,3,
Salvatore Fioriniello3, Maurizio D’Esposito2,3, Simona Marchitti2, Michele Madonna2, Simona Baima4, Giorgio Morelli4,
Sebastiano Sciarretta2,5, Luigi Sironi6,7, Paolo Gelosa7 and Massimo Volpe1,2
UCP2maps nearby the lod score peak of STR1-stroke QTL in the SHRSP rat strain. We explored the potential contribution of UCP2
to the high-salt diet (JD)-dependent increased stroke susceptibility of SHRSP. Male SHRSP, SHRSR, two reciprocal SHRSR/SHRSP-
STR1/QTL stroke congenic lines received JD for 4 weeks to detect brain UCP2 gene/protein modulation as compared with regular
diet (RD). Brains were also analyzed for NF-κB protein expression, oxidative stress level and UCP2-targeted microRNAs expression
level. Next, based on knowledge that fenofibrate and Brassica Oleracea (BO) stimulate UCP2 expression through PPARα
activation, we monitored stroke occurrence in SHRSP receiving JD plus fenofibrate versus vehicle, JD plus BO juice versus BO
juice plus PPARα inhibitor. Brain UCP2 expression was markedly reduced by JD in SHRSP and in the (SHRsr.SHRsp-(D1Rat134-
Mt1pa)) congenic line, whereas NF-κB expression and oxidative stress level increased. The opposite phenomenon was observed
in the SHRSR and in the (SHRsp.SHRsr-(D1Rat134-Mt1pa)) reciprocal congenic line. Interestingly, the UCP2-targeted
rno-microRNA-503 was significantly upregulated in SHRSP and decreased in SHRSR upon JD, with consistent changes in the
two reciprocal congenic lines. Both fenofibrate and BO significantly decreased brain microRNA-503 level, upregulated UCP2
expression and protected SHRSP from stroke occurrence. In vitro overexpression of microRNA-503 in endothelial cells
suppressed UCP2 expression and led to a significant increase of cell mortality with decreased cell viability. Brain UCP2
downregulation is a determinant of increased stroke predisposition in high-salt-fed SHRSP. In this context, UCP2 can be
modulated by both pharmacological and nutraceutical agents. The microRNA-503 significantly contributes to mediate brain UCP2
downregulation in JD-fed SHRSP.
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The SHRSP represents a suitable animal model for the
investigation of the etiopathogenetic basis of hypertensive
target organ damage.1 Feeding SHRSP with JD accelerates
both renal and cerebrovascular damage occurrence2,3
with renal damage preceding stroke.2,4,5 The gene
encoding UCP2 maps nearby the lod score peak of
STR1/stroke QTL identified on rat chromosome 1 in the
SHRSP.3 UCP2 is a inner mitochondrial membrane protein
that exerts an antioxidant effect in various tissues by
regulating fatty acid oxidation, mitochondrial biogenesis,
substrate utilization and ROS elimination,6 and is regulated
by PPARα.7 The latter, a member of nuclear receptor
family of ligand-activated transcription factors, is known to
regulate lipid and energy metabolism through the uncoupling
proteins;7 it also exerts anti-inflammatory and antio-
xidant effects in many cell types, including cardiovascular
cells.8
UCP2 downregulation associates with increased oxidative
stress, atherosclerosis, vascular damage and shorter lifespan
in mice.9–12 UCP2 overexpression significantly prevented
ROS production in endothelial cells and preserved endothelial
function by reducing ROS levels.13,14 Consistently with its
ability to decrease endogenousmitochondrial ROSproduction
and to maintain normal mitochondrial membrane potential
and ATP levels, a neuroprotective effect of UCP2 has been
previously described both in vitro and in vivo.15–21 We
previously reported an age-related spontaneous decrease of
UCP2 gene and protein expression only in the brain of SHRSP,
preceding spontaneous stroke occurrence at 1 year of age.22
Of interest, we have shown that, in association with
increased renal injury, JD significantly downregulates UCP2
gene and protein expression in the kidneys of SHRSP, but not
of SHRSR.23 Consistent findings were obtained in the kidneys
of SHRSR/SHRSP-derived stroke congenic lines, depending
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on the genetic configuration of the transferredUCP2.24 In vitro,
UCP2 silencing in renal mesangial cells led to increased
inflammation, oxidative stress and cell mortality.23 Exposure of
primary renal proximal tubular epithelial cells isolated from
SHRSP to high-NaCl medium led to UCP2 downregulation
and reduced viability, which was rescued by recombinant
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UCP2.24 Moreover, the PPARα-mediated upregulation of
UCP2 gene and protein expression by BO sprouts juice,
administered along with JD, completely prevented renal
damage occurrence in SHRSP.25 As expected, the selective
inhibition of PPARα reduced the beneficial effects of BO on the
renal injury of this strain.25
Notably, fenofibrate, a compound that exerts renal and
neuroprotection in various experimental settings through its
impact on several antioxidant enzymes,26–28 and that is also
known to stimulate PPARα and UCP2 expression,29 promoted
protection from target organ damage in SHRSP.30
Based on the above-mentioned observations, the aims of
the present study were: (1) to assess for the first time the
modulation of UCP2 in the brain of high-salt-fed SHRSP
versus SHRSR, as well as in two SHRSR/SHRSP-STR1/QTL
stroke congenic lines; (2) to explore the impact of PPARα and
UCP2 expression modulation by BO and fenofibrate on the
stroke susceptibility of high-salt-fed SHRSP; and (3) to explain
part of the mechanisms underlying brain UCP2 downregula-
tion upon JD in the stroke-prone strain.
Results
Impact of 4 weeks JD feeding on brain UCP2 expression
and related inflammatory and oxidative stress para-
meters in the four rat lines. Four weeks of JD feeding
induced a significant UCP2 gene and protein expression
downregulation only in the SHRSP brain (Figures 1a–c), as
previously reported in the kidneys.23–25 The (SHRsp.SHRsr-
(D1Rat134-Mt1pa)) congenic line, derived from the SHRSP
parental strain and carrying the SHRSR/STR1 chromosomal
fragment, did not downregulate UCP2 under JD, differently
from the SHRSP strain of origin (Figures 1d and e). Vice
versa, the (SHRsr.SHRsp-(D1Rat134-Mt1pa)) congenic line,
derived from the SHRSR parental strain and carrying the
SHRSP/STR1 chromosomal fragment, significantly down-
regulated UCP2 under JD, differently from the SHRSR strain
of origin (Figures 1f and g). These results confirmed the key
role of UCP2 configuration (SP or SR) for the response to
high-salt diet.
Figure 2 shows the NF-κBprotein expression level, amarker
of inflammation, and the carbonylated protein level, a marker
of oxidative stress, in the brains of the parental lines (SHRSR:
panels a and b; SHRSP: panels c and d). Both inflammatory
and oxidative stress markers were significantly increased only
in the brains of JD-fed SHRSP. Figure 3 shows the same
parameters in the two STR1/QTL stroke congenic lines, the
one derived from the SHRSP (panels a and b), and the one
derived from the SHRSR (panels c and d). Both inflammatory
and oxidative stress markers were decreased in the
SHRSP-derived stroke congenic line, carrying the SHRSR/
STR1 chromosomal fragment (panels a and b), whereas these
markers increased significantly in the SHRSR-derived stroke
congenic line carrying the SHRSP/STR1 chromosomal frag-
ment (panels c and d). These results confirmed that, whenever
UCP2 expression was downregulated, such as in JD-fed
SHRSP and JD-fed (SHRsr.SHRsp-(D1Rat134-Mt1pa)), the
degree of inflammation and of oxidative stress increased. Vice
versa, no increase of these processes was detected in the
brains of both JD-fed SHRSR and JD-fed (SHRsp.SHRsr-
(D1Rat134-Mt1pa)), both carrying higher levels of brainUCP2
expression (as compared with the other two lines).
Impact of fenofibrate administration on brain UCP2
expression and on stroke occurrence in JD-fed SHRSP.
Figure 4 shows the impact of JD plus fenofibrate versus JD
alone on brain UCP2 gene and protein expression, and on
NF-κB and oxidized total protein levels at the end of 4 weeks
of treatment. Fenofibrate could restore UCP2 level (panels a
and b) and decrease levels of both NF-κB and oxidative
stress (panels c–e).
Figure 5 shows the results of the stroke survival study
performed with a long-term fenofibrate administration
(3 months) in JD-fed SHRSP. The impact on UCP2 gene
and protein expression levels in brains of JD plus fenofibrate
treated SHRSP, as compared with animals receiving JD only
and JD plus vehicle, is shown in the panels a and b of the
Figure 5. Also at the end of 3 months of treatment, the parallel
administration of JD and fenofibrate restored UCP2 level
(panels a and b), and decreased levels of both NF-κB and
oxidative stress despite the long-term treatment with JD
(panels c–e). Importantly, fenofibrate fully protected animals
from stroke occurrence over 3 months of follow-up (panel f). In
contrast, occurrence of stroke events reached 100% by the
seventh week of JD in both JD and JD plus vehicle treated rats,
consistently with previous evidence.3,5 SBP and BW values
upon fenofibrate administration are reported in the
Supplementary Table S1.
Impact of BO administration on brain UCP2 expression
and on stroke occurrence in JD-fed SHRSP. Supplemen-
tary Figure S1 shows the impact of JD plus BO versus JD
alone on brain UCP2 gene and protein expression, NF-κB and
oxidized total protein levels at the end of 4 weeks of treatment.
BO restored UCP2 level (panels a and b) and decreased levels
of both NF-κB and oxidative stress (panels c–e).
Figure 6 shows UCP2 gene and protein expression levels,
at different experimental times during the stroke survival study,
in brains of JD plus BO treated rats, as compared with animals
receiving JD only and JD plus BO plus PPARα inhibitor (panels
Figure 1 Characterization of brain UCP2 gene and protein expression upon JD in SHRSR, SHRSP and in the two SHRSR/SHRSP-STR1/QTL stroke congenic lines
(4 weeks of dietary regimen). (a) UCP2 expression in the two parental lines upon either RD or JD; n= 7 for each line for each treatment. ***Po0.0001 for JD versus RD fed
SHRSP, and for JD-fed SHRSP versus JD-fed SHRSR. (b) WB of UCP2 expression in RD and JD-fed SHRSR, with corresponding densitometric analysis. ***Po0.0001 for JD
versus RD. (c) WB of UCP2 expression in RD and JD-fed SHRSP, with corresponding densitometric analysis. ***Po0.0001 for JD versus RD. (d) UCP2 expression in the
SHRSP-derived stroke congenic line upon RD or JD; n= 6 for each treatment. (e) WB of UCP2 expression in the SHRSP-derived stroke congenic line upon RD or JD. **Po0.001
for JD versus RD. (f) UCP2 expression in the SHRSR-derived stroke congenic line upon RD or JD. n= 6 for each treatment. **Po0.001 for JD versus RD. (g) WB of UCP2
expression in the SHRSR-derived stroke congenic line upon RD or JD. **Po0.001 for JD versus RD
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Figure 2 Characterization of NF-κB protein expression and of oxidative stress level in brains of JD-fed SHRSR and SHRSP (4 weeks of dietary regimen). (a) WB of NF-κB
expression with corresponding densitometric analysis in SHRSR upon RD or JD. (b) WB of carbonylated total proteins in SHRSR upon RD or JD. Each lane was loaded with
50 μg of total proteins. Lane M, DNP marker. Each sample was run with its own untreated control (C). Normalization for lane protein loading was performed using Coomassie
staining. The corresponding densitometric analysis is shown on the right side of the panel. Bar graphs represent chemiluminescence intensity relative to the gel loading band.
Bands 1 to 5 refer to the most prominent bands on the blots (identified by arrows), whereas total refers to the total chemiluminescence intensity from all bands. (c) WB of NF-κB
expression with corresponding densitometric analysis in SHRSP upon RD or JD. ***Po0.0001 for JD versus RD. (d) WB of carbonylated total proteins in SHRSP upon RD or JD
with corresponding densitometric analysis shown on the right side of the panel. See legend of panel (b). ***Po0.0001 for JD versus RD
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Figure 3 Characterization of NF-κB protein expression and of oxidative stress level in brains of JD-fed SHRSR/SHRSP-STR1/QTL stroke congenic lines (4 weeks of dietary
regimen). (a) WB of NF-κB and (b) of carbonylated total proteins in the SHRSP-derived stroke congenic line upon RD or JD. See legend of Figure 2b, for the WB of carbonylated
total proteins. Bar graphs on the right side represent corresponding densitometric analysis. ***Po0.0001 for JD versus RD. (c) WB of NF-κB and (d) of carbonylated total proteins
in the SHRSR-derived stroke congenic line upon RD or JD and corresponding densitometric analysis shown on the right side. See legend of Figure 2b for the WB of carbonylated
total proteins. ***Po0.0001 for JD versus RD. (d) **Po0.001 for JD versus RD
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Figure 4 Impact of fenofibrate administration for 4 weeks on brain UCP2 modulation, NF-κB protein expression, oxidative stress level in JD-fed SHRSP. (a and b) UCP2 gene
and protein expression levels; (c) NF-κB expression level; (d and e) oxidative stress level; n= 4 for each experimental group. ***Po0.0001 for each comparison
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a and b). As observed at the end of 4 weeks of the combined
treatment, the concomitant administration of JD and BO
restored UCP2 level, decreased levels of both NF-κB and
oxidative stress despite JD (Figures 6c and d and
Supplementary Figure S2), and led to a significant delay of
stroke occurrence (Figure 6e). In fact, 40% of rats survived
until the 11th week of treatment. The PPARα inhibitor
significantly counteracted the stimulatory effect of the BO
juice on UCP2 expression, therefore leading to 100% stroke
occurrence by the eighth week of treatment (Figures 6a–e),
consistently with previous findings.25 The SBP and BW values
upon these treatments are reported in the Supplementary
Table S1.
Analysis of UCP2-targeted microRNAs upon JD versus
RD in brains of SHRSR and SHRSP. Out of the compared
UCP2-targeted microRNAs in the brains of the SHRSR and
SHRSP strains upon the two diets, we detected a remarkable
differential expression, very consistent with the parallel
differential UCP2 expression, for the rno-microRNA-503. In
fact, this miR was remarkably upregulated (42 folds) in the
brain of JD-fed SHRSP whereas it was significantly down-
regulated in the brain of JD-fed SHRSR as compared with RD
(Figure 7a). No other miR showed a significant modulation in
relation to the observed UCP2 expression changes. Based
on the results of the microRNAs screening, we further
explored the modulation of the microRNA-503 expression in
our experimental groups. We discovered that SHRSP
receiving either fenofibrate or BO along with JD showed a
significant reduction of brain miR-503 expression level
(Figures 7b and c). The expected interference by PPARα
inhibitor was observed in SHRSP receiving JD and BO
(Figure 7c). Furthermore, we observed a significant down-
regulation of brain miR-503 level in the JD-fed SHRSP-
derived congenic line containing the SHRSR/STR1 fragment
(Figure 7d), whereas the SHRSR-derived congenic line,
containing the SHRSP/STR1 segment, showed a significant
upregulation of miR-503 upon JD (Figure 7e). Therefore, the
data obtained in the two STR1/QTL stroke congenic lines
reinforced the evidence obtained in the parental lines of
origin.
Impact of microRNA-503 overexpression on viability of
HUVECs. The in vitro overexpression of hsa-miR-503 in
HUVECs showed a marked UCP2 suppression with a linear
dose–response (Figures 8a and b). Importantly, at a miR-503
concentration able to turn off UCP2 expression by 90%, a
significant increase of cell mortality and a significant
decrease of cell viability were observed (Figure 8c). The
impact on cell viability was comparable to that obtained upon
direct UCP2 silencing in HUVECs (Figure 8d).
Discussion
Our study demonstrates that UCP2 gene and protein
expression levels are significantly downregulated by Japa-
nese style dietary feeding in brains of SHRSP but not in brains
of its related control strain, the SHRSR. This phenomenon
was associated with increased inflammation and oxidative
stress. Accordingly, a SHRSR-derived stroke congenic line,
carrying a fragment of the SHRSP-STR1/QTL (containing
UCP2), showed brainUCP2 downregulation under JD feeding
associated with increased inflammation and oxidative stress.
Vice versa, brainUCP2 expression did not decrease, and both
inflammation and oxidative stress were reduced upon JD in
the reciprocal congenic line. Consistently, the administration of
JD plus fenofibrate, known to stimulate UCP2 expression,25
restored brain UCP2 levels, reduced oxidative stress and fully
protected from stroke occurrence the high-salt fed SHRSP.
The administration of BO sprouts extract, another stimulator of
UCP2 expression,25 was also able to delay significantly stroke
occurrence in JD-fed SHRSP. The PPARα inhibitor antag-
onized the beneficial effect of BO, confirming previous
evidence obtained in the kidneys.25 The greater efficacy of
fenofibrate versus BO on stroke protection may be explained
by the additional molecular and pharmacological properties of
the drug.
Of note, NF-κB, which was characterized in the current
study mainly for its important role in inflammation, is a
ubiquitous transcription factor that, due to its wide range of
gene targets, plays several other functions in mammalian
cells, particularly in the nervous system.31
Based on our results, UCP2 appears to play an important
role in the high-salt diet-dependent increased susceptibility to
cerebrovascular events, as well as it does for the increased
susceptibility to kidney damage of SHRSP.23–25 A common
molecular mechanism, dependent onUCP2 suppression, may
underlie the vascular damage observed in different organs of
high-salt-fed SHRSP.
Uncoupling the proton flux through UCP2 is a critical
pathway in the regulation of senescence.8,32,33 The involve-
ment of UCP2 in vascular diseases is known, being demon-
strated in several pathological contexts,9–13 and it represents
the consequence of its key role in the clearance of ROS within
the mitochondria. A neuroprotective effect of UCP2 has been
previously associated with its role on oxidative stress.16–21 An
association of UCP2 with stroke has been described in other
experimental settings.34,35
A major strength of our data relies on the evidence obtained
in the reciprocal SHRSR/SHRSP-STR1/QTL stroke congenic
lines. The stroke phenotype of these lines clearly depends on
the genomic configuration of the inserted chromosomal
segment belonging to STR1, with evidence that the chromo-
somal fragment carrying UCP2 significantly interferes with
stroke occurrence.5 Herein, we report that the introgression of
the stroke-prone STR1 chromosomal segment (carrying
UCP2) within the stroke-resistant genomic background led to
a suppression of UCP2 expression in contrast to the
upregulation of the SHRSR strain. The opposite phenomenon
was observed in the reciprocal congenic line, supporting the
role of the stroke-prone UCP2 configuration to obtain down-
regulation in response to high-salt diet. We recently reported
similar findings on UCP2 gene and protein expression with
regard to renal damage in the same stroke congenic lines.24
A fundamental demonstration of the role of UCP2 in stroke
predisposition of SHRSP was provided by the significant
protective impact of BO and fenofibrate administration, both
stimulator of UCP2 expression,25,26 toward stroke occurrence
despite JD feeding. Of note, our data on fenofibrate as a
UCP2 and stroke in SHRSP
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protective agent toward stroke confirm and extend previous
findings obtained in the same animal model.30
No evidence ofUCP2mutations between the two strainswas
obtained in our previous study.23 In the attempt to unravel, at
least in part, some of the mechanisms underlying brain UCP2
downregulation upon JD in the stroke-prone strain, we search-
ed for mechanisms involved in the translational regulation of
UCP2. As a result, we found that the UCP2 expression
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modulation upon JD in the brains of SHRSP and SHRSR was
related to the microRNA-503. The latter turned out to be
significantly upregulated in high-salt-fed SHRSP, whereas it
was significantly decreased in the SHRSR upon the same diet.
Consistent results were obtained in the two congenic lines,
further supporting the role of this microRNA in UCP2
downregulation. Moreover, treatment with both fenofibrate and
BO counteracted the increase of brain microRNA-503 level and
the suppression of UCP2 expression in JD-fed SHRSP.
Importantly, both treatments, by their ability to restore regular
levels of both microRNA-503 and UCP2, significantly protected
from stroke occurrence the JD-fed SHRSP. Finally, miR-503
overexpression in vitro abolishedUCP2 expression and caused
a high degree of cell mortality, consistently with what observed
upon direct UCP2 silencing. Our results strongly suggest that
miR-503 is a modulator of brain UCP2 expression in high-salt-
fed SHRSP and also in SHRSR. Of note, miR-503 exerts
multiple actions. It is reported as an antiproliferative and
antiangiogenetic factor,36 and a cell cycle regulator; it is
involved in cell adhesion, migration and angiogenesis
processes.37 Its upregulation in diabetes strongly associates
with vascular damage.36,38 On the other hand, a decrease of
miRNA-503 upon losartan treatment is associated with an
improvement of diabetic nephropathy in an animal model of
spontaneous type 2 diabetes.39 Herein, we report the first
evidence that an increase of miR-503 associates with high-salt
induced stroke occurrence, through its ability to modulate brain
UCP2 expression, in an animal model of spontaneous
hypertension and stroke and that, in turn, miR-503 can be
decreased by both pharmacological and nutraceutical
approaches to obtain protection from stroke. Further studies
will address the interaction between PPARα and miR-503 in the
UCP2 regulation. It will be also interesting to characterize the
potential contribution of miRNA-503 in the prevention and/or
amelioration of hypertensive target organ damage with the
available therapeutic antihypertensive strategies.
Our novel findings support the role of microRNAs in the end-
organ damage promotion during hypertension.40 We are also
aware, as a limitation of the current study, that the role of other
still unknown UCP2-targeted brain microRNAs remains to be
determined in our experimental conditions.
In summary, we demonstrate that UCP2 expression
downregulation by high-salt diet associates with increased
stroke predisposition whereas UCP2 upregulation, by both
nutraceutical and pharmacological agents, associates with a
significant stroke protection in high-salt-fed SHRSP. Our data
strengthen the role of UCP2 as a suitable therapeutic target for
stroke. Notably, the microRNA-503 behaves as a key
determinant of the dietary-dependent regulation of UCP2
expression in the brain of SHRSP. Thus, the microRNA-503
has a significant potential in unraveling the mechanisms
underlying stroke pathogenesis and may reveal a promising
therapeutic agent for this disease.
Materials and Methods
Effects of 4 weeks JD feeding on brain UCP2 gene and protein
expression in SHRSP, SHRSR and in the SHRSR/SHRSP-STR1/
QTL stroke congenic lines. The following rat lines were used for this study:
SHRSP, SHRSR, (SHRsp.SHRsr-(D1Rat134-Mt1pa)), (SHRsr.SHRsp-(D1Rat134-
Mt1pa)). The latter two lines are congenic lines carrying the (D1Rat134-Mt1pa)
chromosomal segment of STR1 (containing UCP2) in the SHRSR configuration
within the SHRSP genomic background (SHRsp.SHRsr-(D1Rat134-Mt1pa)) and,
viceversa, in the SHRSP configuration within the SHRSR genomic background
(SHRsr.SHRsp-(D1Rat134-Mt1pa)). The preparation of the congenic lines has been
previously reported.5 By following our standardized experimental protocol, six-week-
old male rats of both parental and congenic lines were fed with either RD or JD for
4 weeks (parental lines, n= 7 for each line at each treatment; congenic lines, n= 6
for each line at each treatment). At the end of 4 weeks of the dietary treatment, after
SBP and BW measurement, animals were killed by cervical dislocation and brains
were removed for molecular analyses. Tissue total RNA and proteins were extracted
by following previously described procedures.22–25 The UCP2 gene and protein
expression levels, the NF-κB protein expression level and carbonylated total
proteins level were assessed by previously described procedures.22–25
Impact of fenofibrate administration on brain UCP2 gene and
protein modulation and on stroke occurrence in JD-fed SHRSP.
In order to fulfill the first aim, male SHRSP received, starting at 6 weeks of age, JD
alone (n= 4), JD plus fenofibrate (150 mg/kg/die, n= 4) or vehicle (1% CMC, n= 4)
administered via gavage for 4 weeks. In order to analyze the impact of fenofibrate
on stroke survival, 6-week-old SHRSP received JD alone (n= 6), JD plus
fenofibrate (n= 6) or JD plus CMC (n= 6). They were monitored for SBP, BW and
stroke occurrence up to 3 months of the dietary plus fenofibrate treatment.
Brains of JD plus fenofibrate treated SHRSP, taken at the end of both 1 month and
3 months of treatment (n= 4 and 6, respectively), were analyzed for UCP2 gene and
protein expression levels, NF-κB protein expression and oxidative stress levels. These
molecular analyses were compared with those obtained in brains of 4-week JD-fed
SHRSP from the above experimental setup and of 4-week JD plus CMC treated SHRSP.
Impact of BO juice administration on brain UCP2 gene and
protein modulation and on stroke occurrence in JD-fed SHRSP.
In order to fulfill the first aim, male SHRSP received, starting at 6 weeks of age, JD
alone (n= 4) or JD plus BO sprouts extract (n= 4) for 4 weeks by following
previously reported procedures.25 In order to explore the impact of BO on stroke
survival, male SHRSP received JD alone (n= 6), JD plus BO (n= 10), JD plus BO
plus PPARα inhibitor (n= 6) as previously reported.25 SBP, BW and stroke
occurrence were monitored up to 3 months of the dietary plus BO juice treatment.
Brains of SHRSP, taken either at the end of 4 weeks or at the time of stroke
occurrence (between the 8th and 12th week of treatment upon BO; between the 7th
and 8th week of treatment upon BO plus PPARα inhibitor), were analyzed for UCP2
gene and protein expression levels, NF-κB protein expression and oxidative stress
levels. These molecular analyses were compared with those obtained in brains of
4-week JD-fed SHRSP from the above experimental setup.
All rats used for the experiments described in the paragraphs 1–3 were maintained at
the animal facility of the Neuromed Institution in strict compliance with the guidelines set
forth by the American Physiological Society. Animal protocols were approved by the
Institutional Animal Care and Use Committee of the Neuromed Institution. Climate was
controlled, and temperature was set at 22 °C. Diurnal 12-h cycles were kept automatically.
Figure 5 Impact of long-term fenofibrate administration on brain UCP2 modulation, NF-κB protein expression, oxidative stress and stroke occurrence in JD-fed SHRSP.
(a) UCP2 expression is shown in SHRSP fed for 4 weeks with RD (n= 7), JD (n= 7), JD plus vehicle (n= 4) and at the end of three months of JD plus fenofibrate treatment
(n= 6). ***Po0.0001 for each comparison. (b) WB of UCP2 expression in the four experimental groups as above with corresponding densitometric analysis. ***Po0.0001 for
each comparison. (c) WB of NF-κB expression in the four experimental groups as above with corresponding densitometric analysis. ***Po0.0001 for each comparison. (d) WB of
carbonylated total proteins in the four experimental groups with corresponding densitometric analysis (e). See legend of Figure 2b, for the WB of carbonylated total proteins.
***Po0.0001 for JD versus RD fed SHRSP; **Po0.001 for JD plus fenofibrate versus JD plus CMC fed SHRSP. (f) Stroke survival rate in the JD, JD plus vehicle and JD plus
fenofibrate treated SHRSP. The comparison of JD plus fenofibrate treated SHRSP versus both JD and JD plus vehicle treated SHRSP was significant, Po0.001
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Animals were housed two or three per cage with free access to RD (containing 22%
protein, 2.7 mg/g Na+, 7.4 mg/g K+, 0.05 mg/g methionine) and tap water, unless stated
otherwise. The JD contained 17.5% protein, 3.7 mg/g K+ and 0.03 mg/g methionine (Lab.
Piccioni, Milan, Italy), and 1% NaCl was added to the drinking water.
Analysis of UCP2-targeted microRNAs expression upon JD
versus RD in brains of SHRSR and SHRSP. Based on the very limited
knowledge of the rat UCP2 brain modulation by targeted microRNAs, we selected
conserved predicted UCP2-targeted microRNAs with all miRSVR scores by
UCP2 and stroke in SHRSP
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searching the www.microrna.org public database. The following miRNAs were
considered in this study: Rno-microRNA-1, let-7a, let-7b, let-7c, let-7d, let-7i, 16, 24,
27a, 34a, 138, 206, 214, 218, 298, 497, 503. The RT-PCR for each microRNA was
performed in triplicate in brain extracts of both parental strains upon the two diets by
specific gene expression Taqman assays (Life Technologies). Based on the
evidence of a significant microRNA-503 upregulation in the brain of JD-fed SHRSP
Figure 6 Impact of long-term administration of BO on brain UCP2 modulation, NF-κB protein expression, oxidative stress levels and on stroke occurrence in JD-fed SHRSP.
(a) UCP2 expression is shown in SHRSP fed for 4 weeks with RD (n= 7), JD (n= 7) and in SHRSP receiving both JD plus BO at times of stroke occurrence (8 weeks of
treatment, n= 2; 10 weeks, n= 2; 12 weeks, n= 3), SHRSP receiving JD plus BO plus PPARα inhibitor (7 weeks of treatment, n= 4; 8 weeks of treatment, n= 1). ***Po0.0001
for each comparison. (b) WB of UCP2 protein expression in the four experimental groups as above with corresponding densitometric analysis. ***Po0.0001 for each comparison.
(c) WB of NF-κB protein expression in the four experimental groups as above with corresponding densitometric analysis. ***Po0.0001 for each comparison. (d) WB of
carbonylated total proteins in the four experimental groups. See legend of Figure 2b, for the WB of carbonylated total proteins. (e) Stroke survival rate in the JD, JD plus BO, JD
plus BO plus PPARα inhibitor treated SHRSP. The comparison of JD plus BO treated SHRSP versus both JD and JD plus BO plus PPARα inhibitor treated SHRSP was
significant, Po0.001 and Po0.001, respectively
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Figure 7 Analysis of brain rno-microRNA-503 expression level in the different experimental conditions. (a) miR-503 level in the SHRSR and SHRSP upon the two diets.
***Po0.0001 for JD versus RD fed SHRSP; ***Po0.0001 for JD-fed SHRSP versus JD-fed SHRSR; *Po0.05 for JD versus RD fed SHRSR. (b) Impact of fenofibrate
administration for 3 months on miR-503 level in JD-fed SHRSP. ***Po0.0001 for each comparison. (c) Impact of BO alone and of BO plus PPARα inhibitor administration on
miR-503 levels in JD-fed SHRSP. ***Po0.0001 for each comparison. (d) miR-503 level in the SHRSP-derived stroke congenic line upon the two diets. **Po0.001 for JD versus
RD. (e) miR-503 level in the SHRSR-derived stroke congenic line upon the two diets. **Po0.001 for JD versus RD. Rats used for this analysis were the same animals shown in
previous Figures 1–6. For number of animals see the previous figures
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as opposed to a significant downregulation in the brain of SHRSR (see Results
section), the modulation of this miRNA was verified in JD-fed SHRSP upon
fenofibrate, vehicle, BO, BO plus PPARα inhibitor administration, as well as in the
brains of the two SHRSR/SHRSP-STR1/QTL stroke congenic lines (by analyzing
the same rats used in the above described experimental groups).
In vitro hsa-microRNA-503 overexpression in HUVECs. In order to
verify directly the impact of microRNA-503 on UCP2 expression levels, we
performed a dose–response experiment in vitro. For this purpose, HUVECs (Lonza,
Cambrex, Belgium) were seeded in 60-mm well plates (2 × 105 cells/well) and
cultured in endothelial growth medium-2 (EGM-2; Lonza) to reach a 70–80%
confluence. Then, serial concentrations of 12.5, 25, 50, 100, 200 and 400 nM of
hsa-microRNA-503 mimic (Mission microRNA; Sigma-Aldrich (Milan, Italy)) were
incubated in OPTIMEM reduced serum medium with a nucleic acid transferring
agent (lipofectamine RNAiMAX reagent (Invitrogen, Milan, Italy)) in a final volume of
2 ml/well each for 20 min. Five hours later the complex containing medium was
replaced with EGM-2 medium supplemented with 10% fetal bovine serum. Cells
transfected with RNAiMax lipofectamine complex and mission miRNA negative
control (Sigma-Aldrich) were used as control. Twenty-four hours after transfection
cells were extracted for total RNA, by the RNazol procedure,23 and used for the
evaluation of both miR-503 and UCP2 expression levels by RT-PCR. A specific gene
expression Taqman assay (Lifetech, Waltham, MA, USA) was used to assess
miR-503 levels, as reported above. The RT-PCR of UCP2 was performed as
reported above. Finally, we assessed the impact of miR-503 overexpression at
100 nM concentration (corresponding to 90% reduction of UCP2 expression) on cell
apoptosis, necrosis and viability, as assessed by FACS. The results of FACS were
compared with those obtained by performing UCP2 silencing with a specific siRNA
in the same cell line (by following previously reported procedures23).
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Figure 8 Impact of in vitro overexpression of hsa-microRNA-503 on UCP2 expression and cell viability in HUVECs. (a) miR-503 level in HUVECs transfected with different
concentrations of hsa-miR-503. (b) Corresponding UCP2 expression level at each concentration of hsa-miR-503. CTR: control; NEG CTR: cells transfected with lipofectamine
and mission miRNA negative control; D1: 12.5 nM; D2: 25 nM; D3: 50 nM; D4: 100 nM; D5: 200 nM; D6: 400 nM hsa-miR-503. (c) FACS analysis of control cells, lipofectamine-
treated cells (negative control) and of cells overexpressing miRNA-503 (100 nM). ***Po0.0001 and **Po0.001 for each comparison. (d) FACS analysis of UCP2 silenced cells
by using a specific siRNA, compared with both control cells and negative control. ***Po0.0001 and **Po0.001 for each comparison. Each experiment was performed in
triplicate. P=NS for comparison of UCP2 siRNA versus mimic hsa-microRNA-503
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Statistical analysis. All values are shown as means±S.E.M. Statistical
analysis of SBP, BW, RT-PCR, WB densitometric values and FACS values was
performed by one-way ANOVA followed by Bonferroni post hoc test. Comparisons
between two groups were performed using Student's t-test followed by post hoc
Mann–Whitney test. Survivor function in rats monitored over JD feeding alone,
compared with JD plus the different treatments, was estimated by the life-table method.
Log-rank and Wilcoxon statistics were used for testing equality of survivor functions.
Statistical significance was stated at the Po0.05 level. GraphPad Prism (Ver 5.01
GraphPad Software, Inc., La Jolla, CA, USA) statistical software was used for the
statistical analysis.
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